Canakinumab Subcutaneous and Sinequan (Doxepin Oral Concentrate)
Determining the interaction of Canakinumab Subcutaneous and Sinequan (Doxepin Oral Concentrate) and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: canakinumab
Brand name: Ilaris
Synonyms: Canakinumab
Generic Name: doxepin
Brand name: Sinequan, Sinequan, Silenor
Synonyms: Sinequan Capsules, Sinequan
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Canakinumab Subcutaneous-Sinex Long-Acting
- Canakinumab Subcutaneous-Sinex Nasal Spray
- Canakinumab Subcutaneous-Singulair
- Canakinumab Subcutaneous-Singulair (Montelukast Chewable Tablets)
- Canakinumab Subcutaneous-Singulair (Montelukast Oral Granules)
- Canakinumab Subcutaneous-Singulair (Montelukast Tablets)
- Sinequan (Doxepin Oral Concentrate)-Canasa
- Sinequan (Doxepin Oral Concentrate)-Canasa Pac rectal
- Sinequan (Doxepin Oral Concentrate)-Canasa rectal
- Sinequan (Doxepin Oral Concentrate)-Cancidas
- Sinequan (Doxepin Oral Concentrate)-Candesartan
- Sinequan (Doxepin Oral Concentrate)-Candesartan and Hydrochlorothiazide